Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Chemical Engineering
Causes Of Proteolytic Degradation Of Secreted Recombinant Proteins Produced In Ethylotrophic Yeast Pichia Pastoris: Case Study With Recombinant Ovine Interferon-T, Jayanta Sinha, Bradley A. Plantz, Mehmet Inan, Michael Meagher
Causes Of Proteolytic Degradation Of Secreted Recombinant Proteins Produced In Ethylotrophic Yeast Pichia Pastoris: Case Study With Recombinant Ovine Interferon-T, Jayanta Sinha, Bradley A. Plantz, Mehmet Inan, Michael Meagher
Papers in Biotechnology
It was observed that during fermentative production of recombinant ovine interferon-H (r-oIFN-H ) in Pichia pastoris, a secreted recombinant protein, the protein was degraded increasingly after 48 h of induction and the rate of degradation increased towards the end of fermentation at 72 h, when the fermentation was stopped. Proteases, whose primary source was the vacuoles, was found in in-creasing levels in the cytoplasm and in the fermentation broth after 48 h of induction and reached maximal values when the batch was completed at 72 h. Protease levels at various cell fractions as well as in the culture supernatant were …
Haemophilic Factors Produced By Transgenic Livestock: Abundance That Can Enable Alternative Therapies Worldwide, Kevin E. Van Cott, Paul E. Monahan, Timothy C. Nichols, William H. Velander
Haemophilic Factors Produced By Transgenic Livestock: Abundance That Can Enable Alternative Therapies Worldwide, Kevin E. Van Cott, Paul E. Monahan, Timothy C. Nichols, William H. Velander
Papers in Biotechnology
Haemophilia replacement factors, both plasma-derived and recombinant, are in relatively short supply and are high-cost products. This has stymied the study and development of alternative methods of administration of haemophilia therapy even in the most economically advanced countries, owing to the large amounts of material needed because bioabsorption and bioavailability of haemophilic factors can be less than 10% when using non-intravenous routes of delivery. There is therefore a need to increase access to therapy worldwide by decreasing the cost and increasing the abundance so that therapy can be achieved through simplified, alternative delivery methods. Transgenic livestock have been used to …
Production And Purification Of A Chimeric Monoclonal Antibody Against Botulinum Neurotoxin Serotype A , Mark C. Mowry, Michael Meagher Lead Investigator, Leonard Smith, Anuradha Subramanian
Production And Purification Of A Chimeric Monoclonal Antibody Against Botulinum Neurotoxin Serotype A , Mark C. Mowry, Michael Meagher Lead Investigator, Leonard Smith, Anuradha Subramanian
Papers in Biotechnology
Production of recombinant antibodies against botulinum neurotoxin is necessary for the development of a post-exposure treatment. CHO-DG44 cells were transfected with a plasmid encoding the light and heavy chains of a chimeric monoclonal antibody (S25) against botulism neurotoxin serotype A. Stable cell lines were obtained by dilution cloning and clones were shown to produce nearly equivalent levels of light and heavy chain antibody by an enzyme-linked immunosorbent assay (ELISA). In suspension culture, cells produced 35 μg/ml of chimeric antibody after 6 days, corresponding to a specific antibody productivity of 3.1 pg/cell/day. A method for the harvest and recovery of an …